40+ Popular Drug Discovery Targets: A Comprehensive Guide

40+ Popular Targets in Drug Discovery & Design: A Comprehensive Guide

This guide explores over 40 popular targets for drug discovery and design, providing valuable insights for researchers, students, and anyone interested in this dynamic field. While rankings are subjective and can change, the list highlights key targets and companies driving innovation.

Note: This list is not exhaustive; many other targets and companies contribute to drug discovery.

Popular Drug Targets Ranked by Popularity

1. CD47: A cell surface protein overexpressed in various cancers; targeted to enhance anti-tumor immunity.2. HER2 (Human Epidermal Growth Factor Receptor 2): Overexpressed in certain aggressive cancers, targeted by therapies to inhibit tumor growth.3. PD-1 (Programmed Cell Death Protein 1): A checkpoint protein exploited by tumors to evade immune responses; targeted by immune checkpoint inhibitors for cancer immunotherapy.4. EGFR (Epidermal Growth Factor Receptor): Involved in cell growth and proliferation; targeted in various cancers.5. BTK (Bruton's Tyrosine Kinase): Crucial for B cell development and function; targeted in B cell malignancies and autoimmune diseases.6. PARP (Poly ADP Ribose Polymerase): Involved in DNA repair; targeted in cancers with defective DNA repair mechanisms.7. KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog): Frequently mutated in cancers; targeted by novel therapies to inhibit its oncogenic activity.8. VEGFR (Vascular Endothelial Growth Factor Receptor): Essential for angiogenesis (blood vessel formation); targeted to inhibit tumor vascularization.9. PI3K (Phosphoinositide 3-Kinase): A key signaling pathway involved in cell growth, survival, and metabolism; targeted in cancer and other diseases.10. ALK (Anaplastic Lymphoma Kinase): Involved in cell growth and survival; targeted in certain lymphomas and lung cancers.11. BCR-ABL (Breakpoint Cluster Region-Abelson): An oncogenic fusion protein found in chronic myeloid leukemia; targeted by tyrosine kinase inhibitors.12. CD20: A cell surface protein found on B cells; targeted in B cell lymphomas and autoimmune diseases.13. CDK4/6 (Cyclin-Dependent Kinase 4/6): Regulators of the cell cycle; targeted in cancers to inhibit cell proliferation.14. FGFR (Fibroblast Growth Factor Receptor): Involved in cell growth, differentiation, and angiogenesis; targeted in various cancers.15. HER3 (Human Epidermal Growth Factor Receptor 3): Often co-expressed with HER2; targeted in combination therapies.16. JAK (Janus Kinase): Involved in cytokine signaling; targeted in autoimmune diseases and cancers.17. CD38: A cell surface receptor involved in immune responses; targeted in multiple myeloma and other cancers.18. IDH (Isocitrate Dehydrogenase): Mutated in certain cancers, leading to metabolic dysregulation; targeted by specific inhibitors.19. HDAC (Histone Deacetylase): Enzymes that regulate gene expression; targeted in cancers and other diseases.20. CD123: Overexpressed in certain leukemias; targeted by antibody-drug conjugates and other therapies.

Other Important Targets:

• CD28* CD52* CD33* CD19* CD80/86* CDK9, CDK7, CDK12, CDK2, CDK1, CDK5, CDK8, CDK6, CDK11, CDK3, CDK10, CDK13, CDK14, CDK15, CDK16: Cyclin-dependent kinases involved in various cellular processes; targeted for cancer and other diseases.

Companies Working on These Targets

This list represents a selection of companies actively involved in drug discovery research for the listed targets.

• CD47: Forty Seven Inc., Trillium Therapeutics* HER2: Genentech, Pfizer, AstraZeneca* PD-1: Bristol-Myers Squibb, Merck, Roche* EGFR: Novartis, Pfizer, Boehringer Ingelheim* BTK: AbbVie, Janssen Pharmaceuticals* PARP: AstraZeneca, Pfizer, GlaxoSmithKline* KRAS: Amgen, Mirati Therapeutics, Revolution Medicines* VEGFR: Pfizer, Novartis, Bayer* PI3K: Gilead Sciences, Novartis, Bayer* ALK: Pfizer, Novartis, Takeda Pharmaceuticals* BCR-ABL: Novartis, Bristol-Myers Squibb* CD20: Genentech, Roche, Biogen* CDK4/6: Pfizer, Novartis, Eli Lilly* FGFR: Janssen Pharmaceuticals, Novartis, Bristol-Myers Squibb* HER3: Pfizer, Novartis, AstraZeneca* JAK: Incyte Corporation, Pfizer, Eli Lilly* CD38: Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceuticals* IDH: Agios Pharmaceuticals, Celgene, Daiichi Sankyo* HDAC: Novartis, Celgene, Merck* CD123: Stemline Therapeutics, Cellectis, Pfizer* CD28: Bristol-Myers Squibb, Novartis* CD52: Genzyme Corporation, Roche* CD33: Pfizer, AbbVie, Astellas Pharma* CD19: Novartis, Kite Pharma, Juno Therapeutics* CD80/86: Bristol-Myers Squibb, Merck* Various CDKs: Pfizer, Novartis, and many others

This information serves as a starting point for understanding the complex and constantly evolving landscape of drug discovery and design.